FDA approves AstraZeneca’s asthma drug

3 months ago

(Reuters) – Anglo-Swedish pharmaceutical firm AstraZeneca Plc on Tuesday said the U.S. Food and Drug Administration approved its drug benralizumab, as an add-on treatment for patients with severe asthma aged 12 years and older.

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo

The asthma drug will be marketed under the name Fasenra in the United States.

Fasenra is under regulatory review in the EU, Japan and several other countries, the company said.

Our Standards:The Thomson Reuters Trust Principles.